Blood, antisera, vaccines, toxins and cultures3002 (Harmonized System 1992 for 4-digit)
2020 World Trade: $219B, Rnk 11 / 1217
2020 Top Exporter | Top Importer: $34.1B | $44.9B, Germany | United States
2020 Product Complexity: 1.24, Rnk 112 / 1028
2019 - 2020 Export Growth (CAGR): 12.4%, Rnk 100 / 1217
2018 Mean Tariff: 1.83%, Rnk 1251 / 1259
2020 Share of World Trade: 1.31%, Rnk 11 / 1217
Overview This page contains the latest trade data of Blood, antisera, vaccines, toxins and cultures. In 2020, Blood, antisera, vaccines, toxins and cultures were the world's 11th most traded product, with a total trade of $219B. Between 2019 and 2020 the exports of Blood, antisera, vaccines, toxins and cultures grew by 12.4%, from $195B to $219B. Trade in Blood, antisera, vaccines, toxins and cultures represent 1.31% of total world trade.
Blood, antisera, vaccines, toxins and cultures are a part of Pharmaceutical products. They include Antisera and other blood fractions, Vaccines, human use, Blood, toxins, cultures, medical use, nes, Vaccines, veterinary use, except foot and mouth, and Vaccines, foot and mouth disease, veterinary use.
Exports In 2020 the top exporters of Blood, antisera, vaccines, toxins and cultures were Germany ($34.1B), Ireland ($33B), Switzerland ($30.2B), United States ($29.8B), and Belgium ($21.3B).
Imports In 2020 the top importers of Blood, antisera, vaccines, toxins and cultures were United States ($44.9B), Germany ($25.5B), Belgium ($16.5B), Switzerland ($11.8B), and Netherlands ($11.6B).
Tariffs In 2018 the average tariff for Blood, antisera, vaccines, toxins and cultures was 1.83%, making it the 1251st lowest tariff using the HS4 product classification.
The countries with the highest import tariffs for Blood, antisera, vaccines, toxins and cultures are Iran (20%), French Polynesia (13.4%), Democratic Republic of the Congo (10%), and Pakistan (8.69%). The countries with the lowest tariffs are Angola (0%), Cote d'Ivoire (0%), Egypt (0%), Ghana (0%), and Guinea (0%).
Ranking Blood, antisera, vaccines, toxins and cultures ranks 112th in the Product Complexity Index (PCI).
Description Human blood is used to provide oxygen and nutrients to the tissues and to carry away waste products from the tissues. Animal blood prepared for therapeutic, prophylactic or diagnostic uses is used to study blood-borne diseases and to provide antibodies that are used in the diagnosis of diseases. Antisera and other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, are used in the diagnosis of diseases. Vaccines, toxins, cultures of micro-organisms (excl. yeasts) and similar products are used in the prevention and treatment of diseases.
The following visualization shows the latest trends on Blood, antisera, vaccines, toxins and cultures. Countries are shown based on data availability.
For a full breakdown of trade patterns, visit the trend explorer or the product in country profile.
* Using January 2020 exchange rates when trade data is reported in local currency.
Trade By Country
Top Origin (2020): Germany, $34.1B
Top Destination (2020): United States, $44.9B
Blood, antisera, vaccines, toxins and cultures are the world's 11th most traded product.
In 2020, the top exporters of Blood, antisera, vaccines, toxins and cultures were Germany ($34.1B), Ireland ($33B), Switzerland ($30.2B), United States ($29.8B), and Belgium ($21.3B).
In 2020, the top importers of Blood, antisera, vaccines, toxins and cultures were United States ($44.9B), Germany ($25.5B), Belgium ($16.5B), Switzerland ($11.8B), and Netherlands ($11.6B).
Trade by country
Top Origin Growth (2019 - 2020): Belgium, $5.05B
Top Destination Growth (2019 - 2020): Germany, $5.06B
Between 2019 and 2020, the exports of Blood, antisera, vaccines, toxins and cultures grew the fastest in Belgium ($5.05B), Ireland ($4.86B), Germany ($4.85B), South Korea ($2.77B), and China ($2.5B).
Between 2019 and 2020, the fastest growing importers of Blood, antisera, vaccines, toxins and cultures were Germany ($5.06B), Belgium ($3.53B), United States ($2.33B), Switzerland ($1.87B), and Japan ($1.25B).
Cumulative market share
This chart shows the evolution of the market concentration of exports of Blood, antisera, vaccines, toxins and cultures.
In 2020, market concentration measured using Shannon Entropy, was 3.82. This means that most of the exports of Blood, antisera, vaccines, toxins and cultures are explained by 14 countries.
TOP NET EXPORTER (2020): Ireland, $29B
TOP NET IMPORTER (2020): United States, $15.2B
This map shows which countries export or import more of Blood, antisera, vaccines, toxins and cultures. Each country is colored based on the difference in exports and imports of Blood, antisera, vaccines, toxins and cultures during 2020.
In 2020, the countries that had a largest trade value in exports than in imports of Blood, antisera, vaccines, toxins and cultures were Ireland ($29B), Switzerland ($18.4B), Germany ($8.6B), Belgium ($4.8B), and South Korea ($3.75B).
In 2020, the countries that had a largest trade value in imports than in exports of Blood, antisera, vaccines, toxins and cultures were United States ($15.2B), China ($6.05B), Japan ($4.82B), Canada ($4.32B), and Brazil ($3.05B).
In 2020, the world most traded Blood, antisera, vaccines, toxins and cultures, disaggragated by their HS6 level were Antisera and other blood fractions ($172B), Vaccines, human use ($32.6B), Blood, toxins, cultures, medical use, nes ($10.3B), and Vaccines, veterinary use, except foot and... ($3.89B)
This visualization shows the countries that have an important ratio of their trade related to Blood, antisera, vaccines, toxins and cultures. It is possible to select the main countries that export or import Blood, antisera, vaccines, toxins and cultures in the world, or by continent, as well as select the measure of interest.
The Complexity-Relatedness diagram compares the risk and the strategic value of a product's potential export opportunities. Relatedness is predictive of the probability that a country increases its exports in a product. Complexity, is associated with higher levels of income, economic growth potential, lower income inequality, and lower emissions.
Have questions, comments, or concerns?
Send us an e-mail: [email protected]
v5.1.10 dog